Clinical Scorecard: Dermatological Toxicities Associated with Targeted Cancer Therapies: An In-Depth Analysis of Mechanisms, Treatment Strategies, and Existing Research Gaps—A Narrative Review

At a Glance

Key Highlights

• Cutaneous adverse events (CAEs) can occur in up to 90% of patients on targeted therapies, particularly with EGFR inhibitors.
• Early identification of CAEs can optimize oncological treatment and reduce dose modifications.
• Research and guidelines primarily focus on immune checkpoint inhibitors, leaving other therapies like BRAF and MEK inhibitors underrepresented.
• Skin-targeted management strategies, such as topical corticosteroids and moisturizers, can improve patient quality of life.
• Multiple drug classes, including HER2 and CDK4/6 inhibitors, are in development, expanding the scope of dermatological care.

Guideline-Based Recommendations

Diagnosis

Management

• Implement skin-targeted dermatological management, including topical treatments and patient education, to reduce severity of CAEs.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Acneiform dermatitis and other skin toxicities are common, particularly with EGFR inhibitors in patients with lung and colorectal cancers.

Clinical Best Practices

• Educate patients on potential dermatological side effects of their treatment, including specific signs to watch for.
• Encourage proactive skincare regimens, such as using gentle cleansers and moisturizers, to mitigate skin toxicities.
• Collaborate between oncologists and dermatologists for comprehensive care, including regular skin assessments.

References

• Source Article